secwatch / observer
8-K filed May 28, 2026, 5:06 PM ET ticker ALLO CIK 0001737287
leadership confidence high sentiment neutral materiality 0.65

Allogene appoints Zachary Roberts as CEO effective July 1, 2026; David Chang becomes non-employee director

Allogene Therapeutics, Inc.

item 5.02

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-245484
form_type
8-K
ticker
ALLO
cik
0001737287
company_name
Allogene Therapeutics, Inc.
filed_at
2026-05-28T21:06:28+00:00
discovered_at
2026-05-28T21:08:00.315904+00:00
generated_at
2026-05-28T21:15:21.054418+00:00
sec_items
["5.02"]
event_type
leadership
sentiment
neutral
materiality_score
0.65
calibrated_materiality_score
0.65
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-245484
json_url
https://secwatch.observer/filing/0001193125-26-245484.json
markdown_url
https://secwatch.observer/filing/0001193125-26-245484.md
text_url
https://secwatch.observer/filing/0001193125-26-245484.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/d65280d8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Zachary Roberts

President and Chief Executive Officer
ALLO · Allogene Therapeutics, Inc.
Effective
2026-07-01
Filed
May 28, 2026, 5:06 PM ET
the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.
Appointed

David Chang

non-employee director
ALLO · Allogene Therapeutics, Inc.
Effective
2026-07-01
Filed
May 28, 2026, 5:06 PM ET
Dr. Chang will remain on the Board and will become a non-employee director commencing on the Effective Date
Departed

David Chang

President and Chief Executive Officer
ALLO · Allogene Therapeutics, Inc.
Effective
2026-06-30
Successor
Zachary Roberts
Filed
May 28, 2026, 5:06 PM ET
Dr. Chang’s last day of service in these positions will be June 30, 2026.
Role change (interim)

Zachary Roberts

Chief Medical Officer (interim)
ALLO · Allogene Therapeutics, Inc.
Effective
2026-07-01
Filed
May 28, 2026, 5:06 PM ET
Dr. Roberts currently serves as the Company’s Executive Vice President, Research and Development, and Chief Medical Officer and will continue serving as the Company’s Chief Medical Officer on an interim basis following the Effective Date.
Appointed

Zachary Roberts

Class I director
ALLO · Allogene Therapeutics, Inc.
Effective
2026-07-01
Filed
May 28, 2026, 5:06 PM ET
Effective on the Effective Date, Dr. Roberts was also appointed to the Board as a Class I director

Source-grounded claims

18865b97bf

Zachary Roberts was appointed as President and Chief Executive Officer at Allogene Therapeutics, Inc..

the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

1bad2c1b70

David Chang was appointed as non-employee director at Allogene Therapeutics, Inc..

Dr. Chang will remain on the Board and will become a non-employee director commencing on the Effective Date

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

251b68b71b

David Chang resigned as President and Chief Executive Officer at Allogene Therapeutics, Inc..

Dr. Chang’s last day of service in these positions will be June 30, 2026.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

43fe04daa5

Zachary Roberts changed role as Chief Medical Officer (interim) at Allogene Therapeutics, Inc..

Dr. Roberts currently serves as the Company’s Executive Vice President, Research and Development, and Chief Medical Officer and will continue serving as the Company’s Chief Medical Officer on an interim basis following the Effective Date.

SEC 8-K Item 5.02 confidence 0.8 SEC evidence

d2e8883ed6

Zachary Roberts was appointed as Class I director at Allogene Therapeutics, Inc..

Effective on the Effective Date, Dr. Roberts was also appointed to the Board as a Class I director

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Comparable filings

CRVL

CorVel CEO Michael Combs to become Executive Chair; Sarah Scott appointed CEO and President effective July 1, 2026

CORVEL CORP June 1, 2026, 5:05 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.

Comparable filing

In connection with the leadership transition, the Board appointed Sarah Scott to serve as Chief Executive Officer and President of the Company, effective July 1, 2026.

Filing page SEC filing

WTTR

Select Water Solutions COO Skarke moves to Chief Commercial Officer; no successor named

Select Water Solutions, Inc. June 1, 2026, 5:00 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.

Comparable filing

Effective June 1, 2026, Michael C. Skarke transitioned from serving as the Executive Vice President and Chief Operating Officer of Select Water Solutions, Inc. (the “Company”) to serving as the Company’s Executive Vice President and Chief Commercial Officer,

Filing page SEC filing

TTD

The Trade Desk appoints Nate Olmstead as CFO effective July 9, 2026; interim CFO Davis resumes CAO role

Trade Desk, Inc. June 1, 2026, 4:35 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.

Comparable filing

On June 1, 2026, The Trade Desk, Inc. (the “Company”) announced the appointment of Nate Olmstead, age 54, as the Company’s chief financial officer.

Filing page SEC filing

WST

West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair

WEST PHARMACEUTICAL SERVICES INC June 1, 2026, 4:32 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.

Comparable filing

As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.

Filing page SEC filing

LPX

LP Building Solutions announces CFO succession: Alan Haughie to retire; Aaron Howald named CFO effective Sept 1, 2026

LOUISIANA-PACIFIC CORP June 1, 2026, 4:31 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.

Comparable filing

On May 27, 2026, Alan J.M. Haughie, Executive Vice President and Chief Financial Officer of Louisiana-Pacific Corporation (“LP”, the “Company”), notified the Board of Directors of LP (the “Board”) of his intention to retire from the role of Executive Vice President and Chief Financial Officer, effective September 1, 2026.

Filing page SEC filing

VRRM

Verra Mobility CEO David Roberts steps down amid cost realignment; interim CEO Keyser appointed

VERRA MOBILITY Corp June 1, 2026, 4:29 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.

Comparable filing

On June 1, 2026, Verra Mobility Corporation (the “Company”) announced that the Board of Directors of the Company (the “Board”) approved the appointment of Jonathan Keyser as the Interim President and Chief Executive Officer of the Company, effective May 31, 2026.

Filing page SEC filing

PENG

Penguin Solutions CFO Nate Olmstead to step down; Aaron Johnson named interim CFO; reaffirms FY2026 guidance at high end

Penguin Solutions, Inc. June 1, 2026, 4:17 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.

Comparable filing

On May 31, 2026, the board of directors of the Company appointed Aaron Johnson, the Company’s Vice President, Finance and Accounting, as interim CFO and as the Company’s principal financial and accounting officer, succeeding Mr. Olmstead in these positions effective as of July 9, 2026, on an interim basis until the Company appoints a successor.

Filing page SEC filing

LOGC

ContextLogic appoints Scott Stewart as CFO & COO effective June 1; interim CFO resigns

ContextLogic Holdings Inc. June 1, 2026, 4:15 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.

Comparable filing

On June 1, 2026 the Company also announced the appointment of Scott Stewart, age 53, as Chief Financial Officer and Chief Operating Officer, effective June 1, 2026 (the “Effective Date”).

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-245484
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.